At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 22 enrolled
Drug / intervention
Galantamine +2 moredrug
Likely dose
Galantamine 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life
In Brief
A Phase 4 clinical trial evaluating Galantamine, Nimodipine, and 1 other intervention for Dementia. Completed, enrolled 22 participants.
Detailed Summary
The purpose of this study is to evaluate the combination of galantamine with nimodipine in patients with mixed dementia on cognition and quality of life.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDementia
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedDec 2008
Primary CompletionOct 2009
TodayJul 2026
First PostedDec 25, 2008
Enrollment StartJun 1, 2008
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.5 years ago
Interventions
Galantaminedrug
Galantamine 8 mg/day for one month, followed by 4 weeks of galantamine 16 mg/day. If necessary and well tolerated, dosage of galantamine will be increased to 24 mg/day.
Nimodipinedrug
Nimodipine 30 mg 3 times a day (tid).
Placebodrug
Matching placebo three times a day (tid).